BioHarvest Sciences Inc. ... (BHST)
| Bid | 6.87 |
| Market Cap | 113.56M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -0.8 |
| PE Ratio (ttm) | -8.19 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 7.5 |
| Volume | 8,394 |
| Avg. Volume (20D) | 23,975 |
| Open | 6.49 |
| Previous Close | 6.37 |
| Day's Range | 6.38 - 6.57 |
| 52-Week Range | 0.00 - 7.38 |
| Beta | 1.32 |
About BHST
BioHarvest Sciences Inc. operates as a biotechnology company. The company operates through Nutraceuticals and Pharmaceuticals segments. It develops botanical synthesis platform technology to grow the ingredients in any plant enzymes or cells. The company is leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions in nutraceuticals and pharmaceuticals verticals. It also operates as a contra...
Analyst Forecast
According to 2 analyst ratings, the average rating for BHST stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 98.36% from the latest price.
Stock Forecasts
1 month ago · proactiveinvestors.com
BioHarvest CEO talks Nasdaq uplisting, profit targets - ICYMIBioHarvest Sciences Inc. (NASDAQ:BHST) earlier this week reported its financial results for 2024, showing a 99.00% year-over-year increase in revenue to 25.20 million US dollars. The company said four...
1 month ago · proactiveinvestors.com
BioHarvest shares rise after Q4 results show strong demand for VINIA productsBioHarvest Sciences Inc. (NASDAQ:BHST) reported a 62% year-over-year increase in fourth-quarter revenue, reaching $7.3 million, as the biotechnology company saw strong demand for its VINIA product lin...
1 month ago · seekingalpha.com
BioHarvest Sciences Inc. (BHST) Q4 2024 Earnings Conference Call TranscriptBioHarvest Sciences Inc. (NASDAQ:BHST ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Ilan Sobel - CEO Bar Dichter - CFO Conference Call Participants Anthony Vendetti...
